List of works - Sydney S Lu

Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine

scientific article published on 15 November 2005

Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity

scientific article published on 29 March 2007

CCR2 is required for CD8-induced graft-versus-host disease.

scientific article published on 21 July 2005

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation

scientific article

Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease.

scientific article published on 07 August 2009

Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.

scientific article published on 23 September 2016

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

scientific article published on June 2006

Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration

scientific article published on 22 November 2005

Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

scientific article

Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition

scientific article published on 12 April 2021

Relapse after allogeneic hematopoietic cell therapy.

scientific article published on 24 October 2009

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

scientific article published on 2 June 2017

STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease.

scientific article published on 06 October 2008

Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.

scientific article

Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations

article

The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease

scientific article

List of works by Sydney S Lu

Absence of beta7 integrin results in less graft-versus-host disease because of decreased homing of alloreactive T cells to intestine

Absence of donor T-cell-derived soluble TNF decreases graft-versus-host disease without impairing graft-versus-tumor activity

CCR2 is required for CD8-induced graft-versus-host disease.

Ceacam1 separates graft-versus-host-disease from graft-versus-tumor activity after experimental allogeneic bone marrow transplantation

Cytolytic T cells induce ceramide-rich platforms in target cell membranes to initiate graft-versus-host disease.

Genetic drivers of vulnerability and resistance in relapsed acute lymphoblastic leukemia.

Glucocorticoid-induced TNF receptor family related gene activation overcomes tolerance/ignorance to melanoma differentiation antigens and enhances antitumor immunity.

Keratinocyte growth factor (KGF) is required for postnatal thymic regeneration

Keratinocyte growth factor enhances DNA plasmid tumor vaccine responses after murine allogeneic bone marrow transplantation.

Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition

Relapse after allogeneic hematopoietic cell therapy.

Robust patient-derived xenografts of MDS/MPN overlap syndromes capture the unique characteristics of CMML and JMML.

STAT-3 and ERK 1/2 phosphorylation are critical for T-cell alloactivation and graft-versus-host disease.

Splicing factor SF3B1K700E mutant dysregulates erythroid differentiation via aberrant alternative splicing of transcription factor TAL1.

Synthetic Lethal and Convergent Biological Effects of Cancer-Associated Spliceosomal Gene Mutations

The cytolytic molecules Fas ligand and TRAIL are required for murine thymic graft-versus-host disease